Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Conditions
Interventions
C1 esterase inhibitor [human] liquid
Placebo
Locations
27
United States
Medical Research of Arizona
Scottsdale, Arizona, United States
AIRE Medical of Los Angeles
Santa Monica, California, United States
Bay Area Allergy
Walnut Creek, California, United States
IMMUNOe Research Centers
Centennial, Colorado, United States
Asthma and Allergy Associates PC
Colorado Springs, Colorado, United States
Atlanta Allergy and Asthma Clinic
Marietta, Georgia, United States
Start Date
November 1, 2015
Primary Completion Date
July 24, 2017
Completion Date
July 24, 2017
Last Updated
June 8, 2021
NCT07298447
NCT06842823
NCT05396105
NCT05397431
NCT05469789
NCT07428499
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions